Skip to content
High Tech Early Stage Founded 1988

Cytimmune

CytImmune Sciences is a clinical stage nanomedicine company which discovers, develops and commercializes multifunctional, tumor-targeted cancer therapies. The company was founded in 1988 and headquartered in Rockville, United States. It has raised $15M in early stage funding, with backing from Maryland Venture Fund, Montgomery County Government, Maryland, NIH. The company operates in the High Tech - Nanotechnology,…

📍 Rockville, United States · Nanotechnology,

Funding snapshot

Last roundEarly Stage
Amount$15M
Date28 December 2020
Total raised$15M
Team size6

About

CytImmune Sciences is a clinical stage nanomedicine company which discovers, develops and commercializes multifunctional, tumor-targeted cancer therapies. The company was founded in 1988 and headquartered in Rockville, United States. It has raised $15M in early stage funding, with backing from Maryland Venture Fund, Montgomery County Government, Maryland, NIH. The company operates in the High Tech - Nanotechnology, Life Sciences - Immunotherapy, Life Sciences - Oncology space. Multifunctional and tumor-targeted cancer therapies. Its offerings span Oncology - Drugs - Diversified. The company's offerings encompass Nanotechnology - Nanoenabled Products - Life Science - Drugs - Cancer, Oncology - Drugs - Diversified. Within the High Tech - Nanotechnology and Life Sciences - Immunotherapy and Life Sciences - Oncology landscape, the company aims to address evolving market needs through its specialized approach.

Business model

Nanotechnology > Nanoenabled Products > Life Science > Drugs > Cancer,

Oncology > Drugs > Diversified

Institutional investors

Maryland Venture Fund Montgomery County Government Maryland NIH

Latest coverage

No articles yet.

Raising like Cytimmune?

Analyze your pitch deck before your next raise.

Analyze My Deck →